Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | STK10 | O94804 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | YES1 | P07947 | 1/20 | 0.37 |
| ▸ | TEC | P42680 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25213783 | 1.00 | EGFR (0.47) | EGFRFGFR3KDRSTK10ERBB2 | |
| SCHEMBL25247218 | 0.93 | EGFR (0.54) | EGFRKDRSTK10ERBB2YES1 | |
| SCHEMBL30430009 | 0.93 | EGFR (0.54) | EGFRKDRSTK10ERBB2YES1 | |
| SCHEMBL30549077 | 0.92 | EGFR (0.42) | EGFRKDRSTK10ERBB2YES1 | |
| SCHEMBL25209615 | 0.92 | EGFR (0.42) | EGFRKDRSTK10ERBB2YES1 | |
| SCHEMBL25267828 | 0.91 | EGFR (0.59) | EGFRKDRSTK10ERBB2YES1 | |
| SCHEMBL30428769 | 0.90 | EGFR (0.43) | EGFRERBB2 | |
| SCHEMBL25254198 | 0.90 | EGFR (0.43) | EGFRERBB2 | |
| SCHEMBL25213282 | 0.90 | EGFR (0.43) | EGFRERBB2 | |
| SCHEMBL30549066 | 0.90 | EGFR (0.43) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885FGFR3 72/4885KDR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.